Buscar en
Actas Urológicas Españolas (English Edition)
Toda la web
Inicio Actas Urológicas Españolas (English Edition) Undetectable PSA after radical prostatectomy is more likely in low burden N+ pro...
Journal Information
Vol. 43. Issue 9.
Pages 480-487 (November 2019)
Download PDF
More article options
Vol. 43. Issue 9.
Pages 480-487 (November 2019)
Original article
Undetectable PSA after radical prostatectomy is more likely in low burden N+ prostate cancer patients when an extended lymph node dissection is performed
Frecuencia de PSA indetectable en pacientes con cáncer de próstata N+ baja carga tras prostatectomía radical y linfadenectomía ampliada
M. Ramírez-Backhausa,
Corresponding author

Corresponding author.
, M.C. Mir Maresmaa, J.M. Mascarósa, R. Bertolob, J. Hernándeza, Á. Gómez Ferrera, J. Casanova-Ramón Borjaa, J.L. Domínguez Escriga, A. Collado-Serraa, A. Calatrava Fonsc, J. Rubio-Brionesa
a Urology Department, Fundacion Insitituto Valenciano de Oncología, Valencia, Spain
b Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
c Pathology Department, Fundacion Insitituto Valenciano de Oncología, Valencia, Spain
Article information
Full Text
Download PDF
Figures (2)
Tables (5)
Table 1. Clinical, pathological and intraoperative characteristics of the studied cohorts.
Table 2. Oncological follow-up data.
Table 3. Univariable and Multivariable Logistic regression analyses for variables independently associated with PSA < 0.01 at 3th month follow-up.
Table 4. Postoperative complications as classified according to Clavien and detailed.
Table 5. Continence outcomes.
Show moreShow less

To analyze the likelihood of undetectable PSA (<0.01 ng/mL) after extended (ePLND) versus standard pelvic lymph-nodes dissection (sPLND) in pN+ patients.

Materials and Methods

The institutional prospectively maintained Prostate Cancer Database was queried for patients who underwent radical prostatectomy with PLND and were found with three or less lymph-nodal metastases between 2007 and 2017. The extension of the PLND was defined according to the number of lymph-nodes (LN) removed. Patients in the 75th or higher percentile of lymph-nodes removed were considered as the ePLND group; patients in the 25th or lower percentile in the sPLND group. Groups were compared in clinical and pathological variables. Student t-test was used for comparing continuous variables; chi-square test was used for categorical variables. Multivariable logistic regression assessed the probability of undetectable PSA at 3rd month postoperatively. Kaplan–Meier method estimated the probability of biochemical recurrence. Differences between the groups were compared by Log-rank test.


1478 patients were treated within the time span considered. 95 with 1–3 lymph-nodal metastases were extracted. After accounting for inclusion criteria, 23 patients with a median of 11 L N removed were included in the sPLND group (25th percentile); 23 patients with >27 L N were included in ePLND group (75th percentile). Surgical time was longer for ePLND. Sixteen patients (69.6%) who underwent ePLND had undetectable PSA postoperatively. At multivariable analysis, the probability of undetectable PSA at 3rd month was higher in patients who received an ePLND (HR = 5.18; IC95% = 1.16–23.11; p = 0.03).


ePLND is more likely to predict undetectable PSA at third month after radical prostatectomy, irrespective of disease characteristics.

Prostate cancer
Pelvic lymph-nodes dissection
Lymph-nodal metastasis
Prostate specific antigen

Analizar la probabilidad de PSA indetectable (<0.01 ng/mL) tras

(DGLP-ampliada) versus disección estándar de los ganglios linfáticos pélvicos (DGLP-estándar) en pacientes pN+.

Materiales y métodos

Se realizó investigación en la base de datos institucional de cáncer de próstata para obtener información sobre pacientes que se sometieron a PR con DGLP con hallazgos de 3 o menos metástasis ganglionares entre 2007 y 2017.

La DGLP ampliada se definió de acuerdo al número de ganglios linfáticos (GL). Los pacientes con un percentil 75 o superior de ganglios linfáticos extraídos conformaron el grupo DGLPa; los pacientes con un percentil 25 o inferior se adjudicaron al grupo DGLPe (DGLP estándar). Se compararon las variables clínicas y patológicas entre ambos grupos. Se utilizó la prueba T de Student para comparar las variables continuas; la prueba de Chi-cuadrado para las variables categóricas. La regresión logística multivariable evaluó la probabilidad de PSA indetectable al tercer mes desde la operación. El método de Kaplan-Meier estimó la probabilidad de recurrencia bioquímica. Las diferencias entre los grupos se compararon mediante la prueba de log-rank.


De1478 pacientes tratados en el periodo de tiempo considerado, se seleccionaron 95 con 3 o menos metástasis en los ganglios linfáticos. Tras aplicar los criterios de inclusión, 23 pacientes con una mediana de 11 G L extraídos se incluyeron en el grupo PGLPe (percentil 25) y 23 pacientes con >27 G L se incluyeron en el grupo PGLPa (percentil 75). El tiempo quirúrgico fue más largo para el grupo de DGLPa. Dieciséis pacientes (69.6%) tratados con DGLPa presentaron PSA indetectable tras la operación. En el análisis multivariable, la probabilidad de PSA indetectable a los 3 meses fue mayor en los pacientes tratados con DGLPa (HR = 5,18; IC 95% = 1.16–23.11; p = 0.03).


Independientemente de las características de la enfermedad, la DGLPa tiene más probabilidades de predecir un PSA indetectable al tercer mes tras la prostatectomía radical.

Palabras clave:
Cáncer de próstata
Disección de ganglios linfáticos pélvicos
Metástasis ganglionar
Prostate specific antigen


These are the options to access the full texts of the publication Actas Urológicas Españolas (English Edition)

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe to

Actas Urológicas Españolas (English Edition)

Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos